Pub Date : 2023-09-20DOI: 10.53432/2078-4104-2023-22-3-61-69
Yu. N. Yusef, M. V. Budzinskaya, Yu. S. Andreeva, A. A. Plyukhova
PURPOSE. To evaluate the effect of elevated intraocular pressure (IOP) after multiple intravitreal injections (IVI) of brolucizumab on changes in the retinal nerve fiber layer (RNFL) and perfusion of the optic nerve head. METHODS. The study included 20 patients with newly diagnosed exudative form of age-related macular degeneration (AMD). All patients underwent IVI of brolucizumab. IOP measurements were taken with an ICare Pro tonometer before IVI, one minute after IVI, then after 30 minutes and 180 minutes. Thickness of the peripapillary RNFL was measured using Spectralis OCT (Heidelberg Engineering, Germany). The optic disc was examined using OCT angiography on Revo NX (Optopol Technology SA, Poland). All studies were carried out before the start of treatment, after one month, after the third injection, and one year after the start of treatment. RESULTS. Analysis of peripapillary scans in a patient with a history of multiple IVI a year after the start of treatment with brolucizumab showed a statistically significant decrease in perfusion density and fractal dimensions (skeleton) in the entire optic nerve head (ONH) (p<0.001), in the inner ONH area (p<0.001, p=0.01, respectively), in the nasal sector (p=0.03, p=0.04, respectively), temporal sector (p<0.001) and inferotemporal sector (p=0.03) according to OCT angiography. It was determined that a greater increase of IOP one min after IVI was associated with a greater decrease in the density and fractal dimensions of the radial peripapillary capillaries of the inner ONH (p=0.005, rs=0.5; p=0.004, rs=0.6, respectively). A decrease in RNFL thickness was found one year after the start of IVI treatment with brolucizumab (p<0.001). CONCLUSION. According to OCT angiography, vascular perfusion density of the ONH was decreased during IVI of brolucizumab, and RNFL thickness was also decreased one year after the start of treatment.
{"title":"The impact of ocular hypertension on retinal nerve fiber layer and optic disc perfusion during treatment with brolucizumab in patients with neovascular form of age-related macular degeneration","authors":"Yu. N. Yusef, M. V. Budzinskaya, Yu. S. Andreeva, A. A. Plyukhova","doi":"10.53432/2078-4104-2023-22-3-61-69","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-61-69","url":null,"abstract":"PURPOSE. To evaluate the effect of elevated intraocular pressure (IOP) after multiple intravitreal injections (IVI) of brolucizumab on changes in the retinal nerve fiber layer (RNFL) and perfusion of the optic nerve head. METHODS. The study included 20 patients with newly diagnosed exudative form of age-related macular degeneration (AMD). All patients underwent IVI of brolucizumab. IOP measurements were taken with an ICare Pro tonometer before IVI, one minute after IVI, then after 30 minutes and 180 minutes. Thickness of the peripapillary RNFL was measured using Spectralis OCT (Heidelberg Engineering, Germany). The optic disc was examined using OCT angiography on Revo NX (Optopol Technology SA, Poland). All studies were carried out before the start of treatment, after one month, after the third injection, and one year after the start of treatment. RESULTS. Analysis of peripapillary scans in a patient with a history of multiple IVI a year after the start of treatment with brolucizumab showed a statistically significant decrease in perfusion density and fractal dimensions (skeleton) in the entire optic nerve head (ONH) (p<0.001), in the inner ONH area (p<0.001, p=0.01, respectively), in the nasal sector (p=0.03, p=0.04, respectively), temporal sector (p<0.001) and inferotemporal sector (p=0.03) according to OCT angiography. It was determined that a greater increase of IOP one min after IVI was associated with a greater decrease in the density and fractal dimensions of the radial peripapillary capillaries of the inner ONH (p=0.005, rs=0.5; p=0.004, rs=0.6, respectively). A decrease in RNFL thickness was found one year after the start of IVI treatment with brolucizumab (p<0.001). CONCLUSION. According to OCT angiography, vascular perfusion density of the ONH was decreased during IVI of brolucizumab, and RNFL thickness was also decreased one year after the start of treatment.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136313415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-20DOI: 10.53432/2078-4104-2023-22-3-34-43
A. V. Kuroyedov, V. V. Gorodnichiy, O. V. Gaponko, D. V. Grigoriev, S. V. Diordiychuk, D. A. Krivulina, V. V. Mikulik, A. A. Petrov
PURPOSE. To analyze specific clinical and epidemiological parameters of patients with primary open-angle glaucoma (POAG) who were admitted for surgical treatment to the ophthalmological hospital of a multi-specialty in-patient medical center in the period of 2021–2022 years. METHODS. The retrospective elective study analyzed data from 95 patients (95 eyes) with different stages of primary open-angle glaucoma (mean age 73 [67; 80] years old) who were hospitalized for surgical treatment of the disease in 2021–2022. In addition to standard ophthalmological examination, several clinical and epidemiologic characteristics were analyzed in detail, including the prevalence of prescriptions for antiglaucoma hypotensive drugs. Comparison of the obtained results with the data of similar procedures performed in the period from 2005 to 2016 was carried out. RESULTS. The number of main comorbid somatic diseases was on average 3 (2; 4), and comparison of conditions by disease stage revealed no significant differences (p>0.05). Mean duration of the disease (according to anamnesis) was 8 (4; 13) years and was longer in comparison with similar results from 2005–2006 presented in a previous study. The period preceding the first surgical intervention was 5 (2; 10) years and was statistically significantly longer in those with moderate stage of POAG (9 [3; 14] years) compared to those with early stage of POAG (4 [3; 5] years, p<0.05) and advanced stage of POAG (6 [0; 10] years, p<0.04). The average number of drugs at the time of hospitalization for surgical treatment has increased significantly in comparison with the data of the early-mid 2000s and amounted to 4 (3; 4) units (stage I glaucoma — 3 [3; 4]; stage II — 4 [3; 4]; stage III — 4 [3; 4] units), with no statistically significant difference (p1,2=0.64; p1,3=0.21; p2,3=0.42, respectively). CONCLUSION. Unwarranted long-term use of a large number of antiglaucoma drugs ("maximal medication therapy adherence") is a significant problem in modern glaucomatology and can evidently affect future prognosis of the disease.
{"title":"Topical hypotensive therapy preceding surgical treatment of glaucoma","authors":"A. V. Kuroyedov, V. V. Gorodnichiy, O. V. Gaponko, D. V. Grigoriev, S. V. Diordiychuk, D. A. Krivulina, V. V. Mikulik, A. A. Petrov","doi":"10.53432/2078-4104-2023-22-3-34-43","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-34-43","url":null,"abstract":"PURPOSE. To analyze specific clinical and epidemiological parameters of patients with primary open-angle glaucoma (POAG) who were admitted for surgical treatment to the ophthalmological hospital of a multi-specialty in-patient medical center in the period of 2021–2022 years. METHODS. The retrospective elective study analyzed data from 95 patients (95 eyes) with different stages of primary open-angle glaucoma (mean age 73 [67; 80] years old) who were hospitalized for surgical treatment of the disease in 2021–2022. In addition to standard ophthalmological examination, several clinical and epidemiologic characteristics were analyzed in detail, including the prevalence of prescriptions for antiglaucoma hypotensive drugs. Comparison of the obtained results with the data of similar procedures performed in the period from 2005 to 2016 was carried out. RESULTS. The number of main comorbid somatic diseases was on average 3 (2; 4), and comparison of conditions by disease stage revealed no significant differences (p>0.05). Mean duration of the disease (according to anamnesis) was 8 (4; 13) years and was longer in comparison with similar results from 2005–2006 presented in a previous study. The period preceding the first surgical intervention was 5 (2; 10) years and was statistically significantly longer in those with moderate stage of POAG (9 [3; 14] years) compared to those with early stage of POAG (4 [3; 5] years, p<0.05) and advanced stage of POAG (6 [0; 10] years, p<0.04). The average number of drugs at the time of hospitalization for surgical treatment has increased significantly in comparison with the data of the early-mid 2000s and amounted to 4 (3; 4) units (stage I glaucoma — 3 [3; 4]; stage II — 4 [3; 4]; stage III — 4 [3; 4] units), with no statistically significant difference (p1,2=0.64; p1,3=0.21; p2,3=0.42, respectively). CONCLUSION. Unwarranted long-term use of a large number of antiglaucoma drugs (\"maximal medication therapy adherence\") is a significant problem in modern glaucomatology and can evidently affect future prognosis of the disease.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"104 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136308008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-20DOI: 10.53432/2078-4104-2023-22-3-45-51
E. N. Eskina, A. V. Belogurova, V. S. Zinina
PURPOSE. The aim of the study was to evaluate the tolerability and effectiveness of the preservative-free combination eye drops timolol 0,5%/travoprost (Travapress Duo, ROMPHARM Company) when changing therapy in patients with initial and moderate stages of glaucoma after phacoemulsification of age-related cataract. METHODS. The study included 38 patients with disorders of the ocular surface with specific complaints, initial and moderate stages of glaucoma compensated for therapy with β-blockers and prostaglandin F2-α analogues. The patients were using monodrugs of these groups, or their fixed combinations. All patients had previously undergone phacoemulsification of age-related cataract with implantation of a monofocal aspherical intraocular lens. The main group consisted of 18 patients who underwent a change in antiglaucoma therapy to a preservative-free combination eye drops timolol 0,5%/travoprost (Travapress Duo, ROMPHARM Company) with once-per-day instillation regimen. Participants included in the control group (20 patients) remained on the treatment they had been using. All patients completed a questionnaire survey of subjective complaints and their condition, underwent assessment of the level of intraocular pressure (IOP), visual functions, parameters of the state of ocular surface (Schirmer test, epitheliopathy according to the Oxford scale), perimetric data on Humphrey 860 (Humphrey Field Analyzer III 860, Zeiss, USA), as well as morphometric parameters and indicators of retinal blood flow and optic nerve on OCT Cirrus 5000 Angioplex (Zeiss, USA) over three months of observation. RESULTS. After switching the drug all patients of the main group experienced a significant improvement in their subjective condition and gave less complaints about the ocular surface. At the same time, stable IOP compensation and no changes in retinal light sensitivity were achieved according to the results of perimetry, the morphometric data and indicators of retinal and optic nerve blood flow. CONCLUSION. The combined preservative-free eye drops timolol 0,5%/travoprost (Travapress Duo, ROMPHARM Company) is well tolerated by patients and is an effective antiglaucoma drug that allows achieving target IOP level with stabilization of morphological and functional parameters in patients with initial and moderate stages of glaucoma after previous cataract phacoemulsification.
目的。该研究的目的是评估无保存剂噻莫洛尔0.5% /曲沃前列素联合滴眼液(Travapress Duo, ROMPHARM公司)对年龄相关性白内障超声乳化术后初期和中度青光眼患者改变治疗时的耐受性和有效性。方法。该研究纳入了38例眼表疾病患者，这些患者有特定的主诉，初期和中度青光眼，接受β-受体阻滞剂和前列腺素F2-α类似物治疗。患者使用这些组的单一药物，或他们的固定组合。所有患者都曾接受过年龄相关性白内障超声乳化术并植入单焦非球形人工晶状体。主要组由18名患者组成，他们接受了抗青光眼治疗的改变，使用不含防腐剂的噻莫洛尔0.5% /曲伏前列素联合滴眼液(Travapress Duo, ROMPHARM公司)，每天一次滴注。对照组的参与者(20名患者)继续使用他们一直使用的治疗方法。所有患者均完成主观主见及病情问卷调查，评估眼压(IOP)水平、视觉功能、眼表状态参数(Schirmer试验、牛津量表上皮病变)、Humphrey 860(美国蔡司公司Humphrey Field Analyzer III 860)的周边测量数据，以及OCT Cirrus 5000 Angioplex(蔡司公司，美国)的视网膜血流和视神经形态测量参数和指标。美国)超过三个月的观察。结果。转换药物后，所有主组患者的主观状况均有显著改善，对眼表的抱怨减少。同时，根据眼周检查结果、形态计量数据及视网膜和视神经血流指标，获得稳定的IOP代偿，视网膜光敏性无变化。结论。无保存剂噻莫洛尔0.5% /曲沃前列素联合滴眼液(Travapress Duo, ROMPHARM公司)患者耐受性良好，是一种有效的抗青光眼药物，可使既往白内障超声乳化术后早期和中度青光眼患者在稳定形态和功能参数的同时达到目标IOP水平。
{"title":"Effectiveness and tolerability of the fixed combination of preservative-free drugs timolol and travoprost in glaucoma patients after cataract surgery","authors":"E. N. Eskina, A. V. Belogurova, V. S. Zinina","doi":"10.53432/2078-4104-2023-22-3-45-51","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-45-51","url":null,"abstract":"PURPOSE. The aim of the study was to evaluate the tolerability and effectiveness of the preservative-free combination eye drops timolol 0,5%/travoprost (Travapress Duo, ROMPHARM Company) when changing therapy in patients with initial and moderate stages of glaucoma after phacoemulsification of age-related cataract. METHODS. The study included 38 patients with disorders of the ocular surface with specific complaints, initial and moderate stages of glaucoma compensated for therapy with β-blockers and prostaglandin F2-α analogues. The patients were using monodrugs of these groups, or their fixed combinations. All patients had previously undergone phacoemulsification of age-related cataract with implantation of a monofocal aspherical intraocular lens. The main group consisted of 18 patients who underwent a change in antiglaucoma therapy to a preservative-free combination eye drops timolol 0,5%/travoprost (Travapress Duo, ROMPHARM Company) with once-per-day instillation regimen. Participants included in the control group (20 patients) remained on the treatment they had been using. All patients completed a questionnaire survey of subjective complaints and their condition, underwent assessment of the level of intraocular pressure (IOP), visual functions, parameters of the state of ocular surface (Schirmer test, epitheliopathy according to the Oxford scale), perimetric data on Humphrey 860 (Humphrey Field Analyzer III 860, Zeiss, USA), as well as morphometric parameters and indicators of retinal blood flow and optic nerve on OCT Cirrus 5000 Angioplex (Zeiss, USA) over three months of observation. RESULTS. After switching the drug all patients of the main group experienced a significant improvement in their subjective condition and gave less complaints about the ocular surface. At the same time, stable IOP compensation and no changes in retinal light sensitivity were achieved according to the results of perimetry, the morphometric data and indicators of retinal and optic nerve blood flow. CONCLUSION. The combined preservative-free eye drops timolol 0,5%/travoprost (Travapress Duo, ROMPHARM Company) is well tolerated by patients and is an effective antiglaucoma drug that allows achieving target IOP level with stabilization of morphological and functional parameters in patients with initial and moderate stages of glaucoma after previous cataract phacoemulsification.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136313858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-20DOI: 10.53432/2078-4104-2023-22-3-3-13
Kozina E. V., M. V. Теrekhоvich, I. A. Kokh, O. P. Kolesova, N. K. Kondruseva, O. V. Romanovskaya, Yu. T. Lavrinenko
PURPOSE. Assessment of the state of primary disability (PD) caused by glaucoma in the adult population of the Krasnoyarsk Region over time in the period from 2017 to 2021. METHODS. The information from the reporting documentation of the Bureaus of Medical and Social Expertise (MSE) of Russia and the Krasnoyarsk Region for 2017–2021 was analyzed. The analysis of primary disability indicators was carried out for two age groups of the adult population: individuals of working age (men aged 18–59; women aged 18–54) and individuals of retirement age (men aged 60 and older; women aged 55 and older). The obtained results were processed using the Statistica 10.0 software (StatSoft, USA). RESULTS. During 2017–2021 in the Krasnoyarsk Region, 1930 adults were recognized for the first time as disabled due to an ocular pathology. Glaucoma occupied the first ranking place — 31.0% (599) of cases in the structure of primary disability. Individuals of retirement age became disabled in 86.8% (520) of cases. Residents of the cities of the region became disabled in 69.1% (414) of cases. Males dominated among those who were recognized as disabled for the first time (RDF) due to glaucoma — 60.4% (362) of cases. The level of PD for glaucoma among the adult population of the region in 2017 was 0.52, in 2018 — 0.52, in 2019 — 0.59, in 2020 — 0.44, in 2021 — 0.57 per 10 thousand adult population. For five years, there was an increase in the level of PD due to glaucoma by 50% among the able-bodied urban population of the region, by 45.6% among senior citizens, by 110% among the able-bodied village population. In persons of retirement age living in rural areas of the region, the prevalence of PD decreased by 21.1%. The maximum values of the intensive indicator of PD were determined for men of retirement age: in 2017 — 3.6 per 10 thousand, in 2021 — 3.8 per 10 thousand of the corresponding population of the region. Formation of the contingent of disabled people occurred mainly due to the RDF of I and II disability groups. The proportion of group I disability was the largest — 40.4% (242/599) of cases. People with group I disability were more often treated with local antihypertensive drugs, were operated on at stage 3 of glaucoma. CONCLUSION. To reduce primary disability for glaucoma it is necessary to increase preventive efforts, timely use modern methods of diagnosis and treatment, including surgery, and ensure sufficient availability of ophthalmological personnel and high-tech equipment.
{"title":"Primary disability caused by glaucoma in the Krasnoyarsk region","authors":"Kozina E. V., M. V. Теrekhоvich, I. A. Kokh, O. P. Kolesova, N. K. Kondruseva, O. V. Romanovskaya, Yu. T. Lavrinenko","doi":"10.53432/2078-4104-2023-22-3-3-13","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-3-13","url":null,"abstract":"PURPOSE. Assessment of the state of primary disability (PD) caused by glaucoma in the adult population of the Krasnoyarsk Region over time in the period from 2017 to 2021. METHODS. The information from the reporting documentation of the Bureaus of Medical and Social Expertise (MSE) of Russia and the Krasnoyarsk Region for 2017–2021 was analyzed. The analysis of primary disability indicators was carried out for two age groups of the adult population: individuals of working age (men aged 18–59; women aged 18–54) and individuals of retirement age (men aged 60 and older; women aged 55 and older). The obtained results were processed using the Statistica 10.0 software (StatSoft, USA). RESULTS. During 2017–2021 in the Krasnoyarsk Region, 1930 adults were recognized for the first time as disabled due to an ocular pathology. Glaucoma occupied the first ranking place — 31.0% (599) of cases in the structure of primary disability. Individuals of retirement age became disabled in 86.8% (520) of cases. Residents of the cities of the region became disabled in 69.1% (414) of cases. Males dominated among those who were recognized as disabled for the first time (RDF) due to glaucoma — 60.4% (362) of cases. The level of PD for glaucoma among the adult population of the region in 2017 was 0.52, in 2018 — 0.52, in 2019 — 0.59, in 2020 — 0.44, in 2021 — 0.57 per 10 thousand adult population. For five years, there was an increase in the level of PD due to glaucoma by 50% among the able-bodied urban population of the region, by 45.6% among senior citizens, by 110% among the able-bodied village population. In persons of retirement age living in rural areas of the region, the prevalence of PD decreased by 21.1%. The maximum values of the intensive indicator of PD were determined for men of retirement age: in 2017 — 3.6 per 10 thousand, in 2021 — 3.8 per 10 thousand of the corresponding population of the region. Formation of the contingent of disabled people occurred mainly due to the RDF of I and II disability groups. The proportion of group I disability was the largest — 40.4% (242/599) of cases. People with group I disability were more often treated with local antihypertensive drugs, were operated on at stage 3 of glaucoma. CONCLUSION. To reduce primary disability for glaucoma it is necessary to increase preventive efforts, timely use modern methods of diagnosis and treatment, including surgery, and ensure sufficient availability of ophthalmological personnel and high-tech equipment.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136313421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-19DOI: 10.53432/2078-4104-2023-22-3-87-97
I. L. Simakova, L. A. Grigoryan, S. A. Serdiukova
Glaucoma is one of the main causes of low vision and irreversible blindness both in Russia and all over the world. Taking into account the huge budget expenditures of any country, both direct and indirect, required to provide ophthalmological care to a sufficiently large contingent of glaucoma patients, including annual losses of economic productivity associated with visual impairment, the practical importance of glaucoma screening is beyond doubt. In addition, identification of patients at the onset of the disease would allow earlier start of the treatment aimed at stabilizing the glaucoma process. However, the questions remain whether it is possible to perform glaucoma screening in current realities, as well as what research methods should be used. To find the answers to these questions, we reviewed the literature and analyzed modern publications on the problem of glaucoma screening in different countries.
{"title":"The possibility and practicality of glaucoma screening in modern society","authors":"I. L. Simakova, L. A. Grigoryan, S. A. Serdiukova","doi":"10.53432/2078-4104-2023-22-3-87-97","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-87-97","url":null,"abstract":"Glaucoma is one of the main causes of low vision and irreversible blindness both in Russia and all over the world. Taking into account the huge budget expenditures of any country, both direct and indirect, required to provide ophthalmological care to a sufficiently large contingent of glaucoma patients, including annual losses of economic productivity associated with visual impairment, the practical importance of glaucoma screening is beyond doubt. In addition, identification of patients at the onset of the disease would allow earlier start of the treatment aimed at stabilizing the glaucoma process. However, the questions remain whether it is possible to perform glaucoma screening in current realities, as well as what research methods should be used. To find the answers to these questions, we reviewed the literature and analyzed modern publications on the problem of glaucoma screening in different countries.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"182 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135107103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-19DOI: 10.53432/2078-4104-2023-22-3-79-86
A. B. Zakhidov, I. N. Isakov, A. V. Kuroyedov, U. R. Karimov
This review summarizes the results of surgical treatment of far-advanced stage glaucoma in the only seeing eye. A literature search performed in the PubMed search engine and aimed at finding publications reporting the clinical outcomes of treatment in patients with glaucoma in the only seeing eye did yield sufficient data related to the topic. A comprehensive analysis of the available data was performed with an emphasis on the choice of treatment tactics and postoperative results at various times following a surgery. Several studies allowed to perform a comparison of the clinical advantages and cost-effectiveness of medical treatment versus surgery for advanced glaucoma, as well as to assess potential risks and adverse outcomes such as glaucoma progression, postoperative scarring, hypotension and other complications. The results presented in this review suggest that common success criteria can provide uniformity in academic studies, but in daily clinical practice each glaucoma specialist must make a patient-specific decision in favor of either of these methods of treatment in order to guarantee an optimal result, both for the doctor and, of course, for the patient.
{"title":"Risks in the surgical treatment of far-advanced glaucoma in the only seeing eye","authors":"A. B. Zakhidov, I. N. Isakov, A. V. Kuroyedov, U. R. Karimov","doi":"10.53432/2078-4104-2023-22-3-79-86","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-79-86","url":null,"abstract":"This review summarizes the results of surgical treatment of far-advanced stage glaucoma in the only seeing eye. A literature search performed in the PubMed search engine and aimed at finding publications reporting the clinical outcomes of treatment in patients with glaucoma in the only seeing eye did yield sufficient data related to the topic. A comprehensive analysis of the available data was performed with an emphasis on the choice of treatment tactics and postoperative results at various times following a surgery. Several studies allowed to perform a comparison of the clinical advantages and cost-effectiveness of medical treatment versus surgery for advanced glaucoma, as well as to assess potential risks and adverse outcomes such as glaucoma progression, postoperative scarring, hypotension and other complications. The results presented in this review suggest that common success criteria can provide uniformity in academic studies, but in daily clinical practice each glaucoma specialist must make a patient-specific decision in favor of either of these methods of treatment in order to guarantee an optimal result, both for the doctor and, of course, for the patient.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135063085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-19DOI: 10.53432/2078-4104-2023-22-3-98-108
I. A. Bulakh, A. V. Kuroyedov, A. V. Seleznev, Z. M. Nagornova
This review considers possible reasons for the decrease in the effectiveness of antihypertensive treatment in primary open-angle glaucoma (POAG) patients with a family history of the disease, presents clinical practice examples of the effectiveness and duration of antiglaucoma topical therapy and the mechanisms and manifestations of tachyphylaxis and tolerance disorders in such patients. Clinical features and the nature of POAG progression in patients with a hereditary predisposition may be reflected in the early decrease in the effectiveness of antihypertensive treatment. In some recent publications the authors proved a more aggressive course of POAG in patients with a family history of the disease, but despite that, such works at the moment are very limited in number and unsystematized. This, in turn, prevents drawing unambiguous conclusions regarding the features of the prescribed antihypertensive therapy. The article also discusses modern aspects of pharmacogenetics in patients with POAG, its further development will help minimize unwanted side effects as well as increase the effectiveness of antihypertensive drug treatment. The results of the work presented in this review allow systematization of the available data on impaired tolerance to antihypertensive therapy and maintain the need of further clinical research in this area.
{"title":"Specific features of impaired tolerance to antihypertensive treatment in patients with primary open-angle glaucoma and a hereditary history of the disease","authors":"I. A. Bulakh, A. V. Kuroyedov, A. V. Seleznev, Z. M. Nagornova","doi":"10.53432/2078-4104-2023-22-3-98-108","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-98-108","url":null,"abstract":"This review considers possible reasons for the decrease in the effectiveness of antihypertensive treatment in primary open-angle glaucoma (POAG) patients with a family history of the disease, presents clinical practice examples of the effectiveness and duration of antiglaucoma topical therapy and the mechanisms and manifestations of tachyphylaxis and tolerance disorders in such patients. Clinical features and the nature of POAG progression in patients with a hereditary predisposition may be reflected in the early decrease in the effectiveness of antihypertensive treatment. In some recent publications the authors proved a more aggressive course of POAG in patients with a family history of the disease, but despite that, such works at the moment are very limited in number and unsystematized. This, in turn, prevents drawing unambiguous conclusions regarding the features of the prescribed antihypertensive therapy. The article also discusses modern aspects of pharmacogenetics in patients with POAG, its further development will help minimize unwanted side effects as well as increase the effectiveness of antihypertensive drug treatment. The results of the work presented in this review allow systematization of the available data on impaired tolerance to antihypertensive therapy and maintain the need of further clinical research in this area.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"205 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135063083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-18DOI: 10.53432/2078-4104-2023-22-3-109-120
D. I. Ivanov, M. E. Nikulin
In modern ophthalmic surgery, the "gold standard" recognized by most surgeons is ultrasound cataract phacoemulsification, which can’t be said about its antiglaucoma component. Some surgeons prefer to combine phacoemulsification with a filtering surgery, or follow the cyclodestructive approach, but taking into account that the main aqueous humor outflow pathway is through the trabecular meshwork, interventions on the Schlemm’s canal are the most relevant and pathogenetically valid. The article covers the main approaches to surgical interventions aimed at the trabecular meshwork in combination with phacoemulsification, and presents surgical techniques developed by the authors.
{"title":"Comparison of pathogenetically oriented methods aimed at activating the trabecular meshwork in the surgical treatment of cataract","authors":"D. I. Ivanov, M. E. Nikulin","doi":"10.53432/2078-4104-2023-22-3-109-120","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-109-120","url":null,"abstract":"In modern ophthalmic surgery, the \"gold standard\" recognized by most surgeons is ultrasound cataract phacoemulsification, which can’t be said about its antiglaucoma component. Some surgeons prefer to combine phacoemulsification with a filtering surgery, or follow the cyclodestructive approach, but taking into account that the main aqueous humor outflow pathway is through the trabecular meshwork, interventions on the Schlemm’s canal are the most relevant and pathogenetically valid. The article covers the main approaches to surgical interventions aimed at the trabecular meshwork in combination with phacoemulsification, and presents surgical techniques developed by the authors.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135972366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-18DOI: 10.53432/2078-4104-2023-22-3-70-78
M. A. Frolov, Yu. G. Kopchenova, M. P. Tolstykh, A. M. Frolov, F. T Dulani, L. V. Tebueva, A. R. Isaev
This review summarizes the results of surgical treatment of faradvanced stage glaucoma in the only seeing eye. A literature search performed in the PubMed search engine and aimed at finding publications reporting the clinical outcomes of treatment in patients with glaucoma in the only seeing eye did yield sufficient data related to the topic. A comprehensive analysis of the available data was performed with an emphasis on the choice of treatment tactics and postoperative results at various times following a surgery. Several studies allowed to perform a comparison of the clinical advantages and costeffectiveness of medical treatment versus surgery for advanced glaucoma, as well as to assess potential risks and adverse outcomes such as glaucoma progression, postoperative scarring, hypotension and other complications. The results presented in this review suggest that common success criteria can provide uniformity in academic studies, but in daily clinical practice each glaucoma specialist must make a patientspecific decision in favor of either of these methods of treatment in order to guarantee an optimal result, both for the doctor and, of course, for the patient.
{"title":"Risks in the surgical treatment of far-advanced glaucoma in the only seeing eye","authors":"M. A. Frolov, Yu. G. Kopchenova, M. P. Tolstykh, A. M. Frolov, F. T Dulani, L. V. Tebueva, A. R. Isaev","doi":"10.53432/2078-4104-2023-22-3-70-78","DOIUrl":"https://doi.org/10.53432/2078-4104-2023-22-3-70-78","url":null,"abstract":"This review summarizes the results of surgical treatment of faradvanced stage glaucoma in the only seeing eye. A literature search performed in the PubMed search engine and aimed at finding publications reporting the clinical outcomes of treatment in patients with glaucoma in the only seeing eye did yield sufficient data related to the topic. A comprehensive analysis of the available data was performed with an emphasis on the choice of treatment tactics and postoperative results at various times following a surgery. Several studies allowed to perform a comparison of the clinical advantages and costeffectiveness of medical treatment versus surgery for advanced glaucoma, as well as to assess potential risks and adverse outcomes such as glaucoma progression, postoperative scarring, hypotension and other complications. The results presented in this review suggest that common success criteria can provide uniformity in academic studies, but in daily clinical practice each glaucoma specialist must make a patientspecific decision in favor of either of these methods of treatment in order to guarantee an optimal result, both for the doctor and, of course, for the patient.","PeriodicalId":477291,"journal":{"name":"Глаукома","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135972367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：